¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"growth line"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • life line
    1. »ý¸íÀüÈ­ 2. »ý¸í±¸Á¶¼±
  • line
    1. ¼± 2. °è
  • M line
    Áß°£°¡·Î¸·
  • major dense line
    ūġ¹Ð¼±
  • midaxillary line
    Áß°£°Üµå¶û¼±, ¾×¿ÍÁß°£¼±
  • midclavicular line
    ºøÀåÁß°£¼±, ¼â°ñÁß°£¼±
  • milk line
    Á¥¼±, À¯¼±
  • minimal tension line
    ÃÖ¼ÒÀå·Â¼±
  • maternal line
    ¸ð°è
  • mesiolingual line angle
    ¾ÈÂÊÇôÂʼ±°¢
  • mesio-occlusal line angle
    ¾ÈÂʱ³Çո鼱°¢, ¾ÈÂʸ¹°¸²¸é¼±°¢
  • neonatal line
    ½Å»ý¾Æ¼±, ù¼ºÀå¼±
  • nuchal line
    ¸ñ´ú¹Ì¼±
  • nasolabial line
    ÄÚÀÔ¼ú¼±
  • oblique line
    ºø±Ý, »ç¼±
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • single-step growth curve
    ÀÏȸÁõ½Ä°î¼±
  • developmental line
    ¹ß´Þ¼±, ¹ßÀ°À¶ÇÕ¼±
  • diploid cell line
    À̹èü¼¼Æ÷°è
  • double line hemorrhage
    µÎÁÙÃâÇ÷
  • dynamic skin line
    µ¿ÀûÇǺμ±
  • growth defect
    ¼ºÀå°áÇÔ
  • growth delay
    ¼ºÀåÁö¿¬
  • growth-onset diabetes
    Ãʱâ´ç´¢º´
  • embryonic line
    ¹è¾Æ¼±
  • epidermal growth factor
    Ç¥ÇǼºÀåÀÎÀÚ
  • epiphyseal line
    »À³¡¼±, °ñ´Ü¼±
  • established cell line
    È®¸³¼¼Æ÷ÁÖ
  • excessive growth
    °úµµ¼ºÀå
  • exponential growth
    Áö¼öÁõ½Ä
  • exponential growth rate
    ´ë¼öÁõ½Ä·ü, Áö¼öÁõ½Ä·ü
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • anocutaneous line
    Ç×¹®ÇǺμ±
  • anorectal line
    Ç×¹®°ðâÀÚ¼±
  • anterior axillary line
    ¾Õ°Üµå¶û¼±
  • anterior gluteal line
    ¾Õº¼±â±Ù¼±
  • arcuate line
    Ȱ²Ã¼±
  • germ line
    ¹è¼±(ÛÏàÊ).
  • germ line theory
    ³»¸²¹°·Á¹Þ±â¼³ (Ç×ü´Ù¾ç¼ºÀÇ)
  • gingival line
    Ä¡Àº¼±(öÍó»àÊ).
  • gluteal line<³ª> linea glutea
    µÐºÎ±Ù¼±, µÐ±Ù¼±(ÔëÐÉàÊ).
  • gluteal line<³ª> linea glutea
    µÐºÎ±Ù ¼±, µÐ±Ù ¼±(ÔëÐÉàÊ).
  • heteroploid cell line
    À̼öü¼¼Æ÷°è
  • highest nuchal line
    ÃÖ»óÇ×¼±(õÌß¾ú£àÊ).
  • highest nuchal line
    ¸ÇÀ§¸ñ´ú¹Ì¼±
  • highest nuchal line
    ÃÖ»ó Ç× ¼±(õÌß¾ú£àÊ), ¸ÇÀ§ ¸ñ´ú¹Ì ¼±.
  • iliopectineal line
    ÀåÄ¡°ñ¼±(íóö»ÍéàÍ).
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • epidermoid growth factor
    Ç¥ÇÇ¾ç ¼ºÀåÀÎÀÚ(¡­à÷íþì×í­)
  • essential growth factor
    ÇʼöÁõ½ÄÀÎÀÚ
  • excessive growth
    ¼ºÀå°úµµ
  • exponential growth
    Áö¼öÁõ½Ä.
  • exponential growth phase
    Áö¼öÁõ½Ä±â(ÊÙÌ¡ËàË»).
  • exponential growth rate
    ´ë¼öÁõ½Ä·ü, Áö¼öÁõ½Ä·ü
  • exponential phase of growth
    ´ë¼öÁõ½Ä±â, °¡¼Ó¼ºÀå±â.
  • face growth
  • fetal growth retardation
    ÅÂ¾Æ ¹ßÀ° Áö¿¬, ÅÂ¾Æ ¼ºÀå Áö¿¬
  • fibroblast growth factor
    ¼¶À¯¸ð¼¼Æ÷ ¼ºÀåÀÎÀÚ(¡­à÷íþì×í­)
  • fibroblast growth factor(FGF)
    ¼¶À¯¾Æ¼¼Æ÷ ¼ºÀåÀÎÀÚ
  • grain growth
    ÀÔÀÚÀÇ ¼ºÀå.
  • growth
    ¼ºÀå, Áõ½Ä
  • growth abnormality
    ¹ßÀ°ÀÌ»ó.
  • growth abnormality
    ¼ºÀåÀÌ»ó
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • Medial supracondylar line
    ¾ÈÂʰüÀýÀ¶±âÀ§¼±
    [¿¾ ¿ë¾î] ³»Ãø°ú»ó¼±
  • Anterior axillary line
    ¾Õ°Üµå¶û¼±
    [¿¾ ¿ë¾î] Àü¾×¿Í¼±
  • Anterior gluteal line
    ¾Õº¼±â±Ù¼±
    [¿¾ ¿ë¾î] ÀüµÐ±Ù¼±
  • Midsternal line
    ¾ÕÁ¤Áß¼±
    [¿¾ ¿ë¾î] ÀüÁ¤Áß¼±
  • Scapular line
    ¾î±ú»À¼±
    [¿¾ ¿ë¾î] °ß°©¼±
  • Superior temporal line
    À§°üÀÚ¼±
    [¿¾ ¿ë¾î] »óÃøµÎ¼±
  • Superior nuchal line
    À§¸ñ´ú¹Ì¼±
    [¿¾ ¿ë¾î] »óÇ×(¸ñ´ú¹Ì)¼±
  • Intercondylar line
    À¶±â»çÀ̼±
    [¿¾ ¿ë¾î] °ú°£¼±
  • Mammary line
    Á¥²ÀÁö¼±
    [¿¾ ¿ë¾î] À¯µÎ¼±
  • Midaxillary line
    Áß°£°Üµå¶û¼±
    [¿¾ ¿ë¾î] Áß°£¾×¿Í¼±
  • Intermediate line
    Áß°£´É¼±
    [¿¾ ¿ë¾î] Áß°£¼±
  • Neonatal line
    ù¼ºÀå¼±
    [¿¾ ¿ë¾î] ½Å»ý¼±
  • Mylohyoid line
    Åθñ»Ô±Ù¼±
    [¿¾ ¿ë¾î] ¾Ç¼³°ñ±Ù¼±
  • Anorectal line
    Ç×¹®°ðâÀÚ¼±
    [¿¾ ¿ë¾î] Ç×¹®Á÷Àå¼±
  • Anocutaneal line
    Ç×¹®ÇǺμ±
    [¿¾ ¿ë¾î] Ç×¹®ÇǺμ±
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • growth factor
    ¼ºÀåÀÎÀÚ (à÷íþì×í­)
  • growth hormone
    ¼ºÀå(à÷íþ)È£¸£¸ó
  • growth hormone regulatory hormone
    ¼ºÀå(à÷íþ)È£¸£¸ó Á¶Àý(ðàï½) È£¸£¸ó
  • growth hormone release-inhibiting hormone
    ¼ºÀå(à÷íþ) È£¸£¸ó ¹æÃâÀúÇØ (Û¯õóîÁúª) È£¸£¸ó
  • growth hormone releasing hormone
    ¼ºÀå(à÷íþ)È£¸£¸ó ¹æÃâ (Û¯õó)È£¸£¸ó
  • growth medium
    ¼ºÀå¹èÁö (à÷íþÛÆò¢)
  • growth rate constant
    ¼ºÀå¼Óµµ »ó¼ö (à÷íþáÜÓøßÈâ¦)
  • growth retardant
    ¼ºÀåÁö¿¬Á¦(à÷íþòÀæÅð¥)
  • head growth
    ¸Ó¸®¼ºÀå (à÷íþ)
  • headward growth
    ¸Ó¸®ÂÊ ¼ºÀå(à÷íþ)
  • linear growth
    ¼±Çü¼ºÀå(àÊû¡à÷íþ)
  • logarithmic growth
    ´ë¼ö Áõ½Ä(ÓÛâ¦ñòãÖ)
  • molar growth yield
    ¸ô¼ºÀå¼öÀ²(à÷íþâ¥ëÏ)
  • nerve growth factor
    ½Å°æ¼ºÀåÀÎÀÚ(ãêÌèà÷íþì×í­)
  • platelet-derived growth factor
    Ç÷¼ÒÆÇÀ¯·¡(úìá³÷ùë¦ÕÎ) ¼ºÀåÀÎÀÚ(à÷íþì×í­)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
IUGR intrauterine growth rate; intrauterine growth retardation
PGH pituitary growth hormone; porcine growth hormone; prostaglandin H
SGF sarcoma growth factor; skeletal growth factor
LF   1) Lethal Factor
  2) Line Feed
  3) Left Foot
LPM Line Per Minute
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
FLN Fluorescence Line Narrowing
GDNF GLIAL cell-line derived neurotrophic factor
L1 LINE-1
LMG Lethal mid-line granuloma
LIA Line Immunoassay
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • total growth
    ÃÑ Áõ½Ä·®
  • tumor growth
    Á¾¾ç ¼ºÀå
  • uncontrolled destructive growth
    ºñÁ¶Àý¼º ÆÄ±«¼º ¼ºÀå
    ÀÎÀ§ÀûÀ¸·Î Á¶ÀÛÀÌ ¾ÈµÇ°í ÀÚ¶ó¸é¼­ ÆÄ±«Àû ¼ºÁúÀ» Áö´Ï´Â °Í.
  • vascular endothelial growth factor
    ¸Æ°ü ³»ÇǼ¼Æ÷ ¼ºÀå ÀÎÀÚ, Ç÷°ü ³»ÇǼ¼Æ÷ ¼ºÀå ÀÎÀÚ
  • vertical growth
    ¼öÁ÷ ¼ºÀå
  • alveolar line
    Ä¡Á¶¼±, »ó¾Ç¼±
  • alveolar ridge line
    Ä¡Á¶Á¤ ¼±
  • base line
    ±â¼±, ±âÀú¼±, ¹ÙÅÁ¼±
    ¹ÌÁ¤ÀÇ ¾çÀ̳ª °ªÀ» ÃøÁ¤ ¶Ç´Â ÆòÁ¤ÇÏ´Â µ¥ ¾²ÀÌ´Â ±âº»ÀÇ ¾ç ¶Ç´Â °ª.
  • base line shift
    ±âÁؼ± º¯À§
  • blood line
    Ç÷Á·, Ç÷Á·°è
  • Camper's line
    įÆÛ ¼±
    ºñÀÍÀÇ Çϴܰú ¿ÜÀ̵¹±âÀÇ »ó¿¬À» ¿¬°áÇÏ´Â ¼±.
  • cell line
    ¼¼Æ÷°è
  • cement line
    ½Ã¸àÆ® ¼±
    Ä¡°ü º¸Ã¶¹°À» Áö´ëÄ¡¿¡ Ä¡°ú¿ë ÇÕÂøÁ¦·Î ¿µ±¸ ÇÕÂø½ÃÄ×À» ¶§ ºÎÁ¤È®ÇÑ Á¢ÇÕÀ¸·Î ÇÕÂøÁ¦°¡ ³ëÃâµÇ´Â °Í.
  • cemental line
    ½Ã¸àÆ® ¼±
    °ñÀÇ È¾´Ü¸éÀÇ Çö¹Ì°æ °Ë»ç¿¡¼­ °üÂûµÇ´Â ¼±. °ñ´ÜÀ§ÀÇ °æ°è¸¦ ³ªÅ¸³½´Ù.
  • cervical line
    °æ¼±, Ä¡°æ¼±
    Ä¡±Ù°ú Ä¡°üÀÇ °æ°è¸¦ Ä¡°æ¼±À̶óÇÏ°í ¹ý¶û, ¹é¾ÇÁú °æ°è ºÎÀ§¸¦ ¶æÇϸç neck lineÀ̶ó°íµµ ÇÑ´Ù. ÀÌ ¼±Àº ¿µ±¸ ºÒº¯ÀÇ ¼±ÀÌ´Ù.
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
growth control <cell biology> When applied to cells usually means control of growth of the population, i.e. Of the rate of division rather than of the size of an individual cell.
(18 Nov 1997)
growth curve A graphic representation of the change in size of an individual or a population over a period of time.
(05 Mar 2000)
growth disorders Deviations from the average values for a specific age and sex in any or all of the following: height, weight, skeletal proportions, osseous development, or maturation of features. The concept includes both acceleration and retardation of growth.
(12 Dec 1998)
growth factor <biochemistry> A complex family of polypeptide hormones or biological factors that are produced by the body to control growth, division and maturation of blood cells by the bone marrow. They regulate the division and proliferation of cells and influence the growth rate of some cancers. These factors occur naturally but some can be synthesised using molecular biology techniques and are used clinically to stimulate normal white cell production following chemotherapy or bone marrow transplantation.
Examples include epidermal growth factor, platelet-derived growth factor, fibroblast growth factor. Insulin and somatomedin are also growth factors, the status of nerve growth factor is more uncertain. Perturbation of growth factor production or of the response to growth factor is important in neoplastic transformation.
(29 Sep 1997)
growth factors Proteins involved in cell differentiation and growth.Growth factors are essential to the normal cell cycle, and are thus vital elements in the life of animals from conception to death. Among other things, they mediate foetal development, play a role in maintenance and repair of tissues, stimulate production of blood cells, and, gone awry, participate in cancerous processes.
(05 Mar 2000)
growth hormone <endocrinology, hormone> Polypeptide (191 amino acids) produced by anterior pituitary that stimulates liver to produce somatomedins 1 & 2.
(13 Nov 1997)
growth hormone inhibiting hormone <protein> Gastrointestinal and hypothalmic peptide hormone (two forms: 14 and 28 residues), found in gastric mucosa, pancreatic islets, nerves of the gastrointestinal tract, in posterior pituitary and in the central nervous system. Inhibits gastric secretion and motility: in hypothalamus/pituitary inhibits somatotropin release.
(18 Nov 1997)
growth hormone-producing adenoma <tumour> An adenoma that produces the clinical picture of gigantism or acromegaly, although a third of the cells have no granules or are a mixture of acidophils and chromophobes; some tumours may secrete both growth hormone and prolactin; often an acidophil or eosinophil adenoma.
(05 Mar 2000)
growth hormone-regulating hormone <endocrinology> Hypothalamic hormones that induce (somatoliberin) or inhibit (somatostatin) the release of growth hormone (somatotropin).
(18 Nov 1997)
growth hormone-releasing factor <endocrinology> Peptide hormone related to the glucagon family, released from the pituitary, acts on the adenohypophysis to release growth hormone.
Synonym: somatoliberin, growth hormone-releasing factor.
(20 Sep 2002)
growth hormone-releasing hormone <endocrinology> Peptide hormone related to the glucagon family, released from the pituitary, acts on the adenohypophysis to release growth hormone.
Synonym: somatoliberin, growth hormone-releasing factor.
(20 Sep 2002)
growth hormone stimulation test <investigation> A test which measures the level of human growth hormone in response to the administration of the amino acid arginine. This test measures the ability of the pituitary gland to secrete growth hormone. Normal values in children are: 48 ng/ml. Normal values in men are 10 ng/ml. Normal values in women are 15 ng/ml. This test is used to evaluate infants with growth retardation. It may also be part of an evaluation for a pituitary tumour. Failure of arginine to raise growth hormone levels may indicate hypopituitarism or dwarfism.
(27 Sep 1997)
growth hormone suppression test <investigation> A test to determine if growth hormone is suppressed by hyperglycaemia. Growth hormone blood levels are determined sequentially after ingestion of a glucose-rich meal. If growth hormone levels remain elevated (after the glucose is given) then acromegaly or gigantism is suspected.
(27 Sep 1997)
growth inhibitors Endogenous or exogenous substances which inhibit the normal growth of human and animal cells or micro-organisms, as distinguished from those affecting plant growth (= plant growth regulators).
(12 Dec 1998)
growth medium <cell culture> A synthetic medium which is filled with nutrients necessary to the growth of microorganisms or cells being cultured in the lab.
(09 Oct 1997)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • belt line
    ¼øÈ¯¼±
  • bread line
    »§¹è±ÞÀ»¹Þ´Â»ç¶÷
  • building line
    (µµ·Î µûÀ§¿¡ ÀÓÇÏ´Â)°ÇÃàÁ¦ÇѼ±
  • catch line
    ÁÖÀǸ¦ ²ô´Â) ¼±Àü ¹®±¸;Ç¥Á¦
  • chorus line
    ÄÚ·¯½º ¶óÀÎ(ÁÖ¿ª±Þ ¹è¿ì¸¸ÀÌ ³ÑÀ» ¼ö ÀÖ´Â,¹«´ë Àü¸éÀÇ ¹é¼±)
  • chow line
    (±º´ë µî¿¡¼­)±Þ½Ä ¹Þ±â À§ÇØ ¼± ÁÙ
  • coasting line
    ¿¬¾ÈÇ×·Î
  • color line
    (»ç¿Ü.°æÁ¦.Á¤Ä¡Àû) ¹éÀÎ.ÈæÀÎÀÇ Â÷º° À庮
  • contour line
    µî°í¼±;µî½É¼±
  • credit line
    Å©·¹µðÆ®¶óÀÎ(´º½º.±â»ç.»çÁø.±×¸²ÀÇ º¹Á¦ µî¿¡ ºÙÀÌ´Â Á¦°øÀÚÀÇ À̸§ µîÀ» ¾´ °Í);½Å¿ë(¿Ü»ó)Çѵµ¾×;½Å¿ëÀå °³¼³ Çѵµ;½Å¿ëÇѵµ
  • crow line
    ÀÏÁ÷¼±(beeline)
  • date line
    ³¯Â¥ º¯°æ¼±;³¯Â¥±âÀÔ¼±;(±â»çµî¿¡)¹ß½ÅÁö¿Í ³¯Â¥¸¦ ±âÀÔÇÑ´Ù
  • datum line
    ±âÁؼ±
  • destruct line
    (¹Ì»çÀÏÀÇ)ÀÚÆø¼±
  • dotted line
    Á¡¼±;(Áöµµ¿¡ Àû¾î ³ÖÀº)¿¹Á¤ ÄÚ½º;¹«Á¶°Ç µ¿ÀÇÇÏ´Ù
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
ÅëÇÕ°Ë»ö ¿Ï·á